Allergy Section, Medicine Department, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron, 119-129, 08035, Barcelona, Spain.
Expert Opin Biol Ther. 2013 Sep;13(9):1225-8. doi: 10.1517/14712598.2013.822484. Epub 2013 Jul 23.
To collect data on the efficacy and safety of omalizumab in 110 patients from 9 Spanish hospitals suffering from chronic spontaneous urticaria (CSU) refractory to conventional treatment.
A retrospective, descriptive analysis was performed, showing the data of 110 patients suffering from refractory CSU who received omalizumab as an off-label treatment in 9 Spanish hospitals from October 2009 to September 2012.
Ninety (81.8%) patients exhibited a complete or significant response, 12 (10.9%) had partial response, and 8 (7.2%) showed no response. Sixty-six (60%) patients were able to stop all concomitant medications, remaining asymptomatic treated with omalizumab alone. No serious adverse events were reported.
Omalizumab shows excellent efficacy and safety profile in a large series of CSU patients in real-life practice. This drug will contribute to settle the debt with CSU patients contributing to restore their quality of life.
收集来自 9 家西班牙医院的 110 名慢性自发性荨麻疹（CSU）患者对奥马珠单抗疗效和安全性的数据，这些患者对常规治疗无反应。
采用回顾性、描述性分析，显示了 2009 年 10 月至 2012 年 9 月期间，9 家西班牙医院的 110 名接受奥马珠单抗作为超说明书治疗的难治性 CSU 患者的数据。
90 例（81.8%）患者出现完全或显著缓解，12 例（10.9%）患者出现部分缓解，8 例（7.2%）患者无缓解。66 例（60%）患者能够停止所有伴随药物，单独使用奥马珠单抗治疗无症状。未报告严重不良事件。
奥马珠单抗在真实世界实践中对大量 CSU 患者显示出良好的疗效和安全性。该药物将有助于缓解 CSU 患者的病情，恢复他们的生活质量。
